Can GLP-1 injections help with long-term weight loss?

Step 1: what GLP-1 injections are actually doing inside you

The name GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases naturally after eating. Licensed weight-management injections mimic or amplify this signal, binding to receptors in the brain and gut that tell your body it has had enough. Gastric emptying slows. Appetite falls. Food becomes less compelling in a way that has nothing to do with motivation.

Tirzepatide, sold in the UK as Mounjaro, goes a step further by also activating a second receptor (GIP) making it the only dual-agonist weight-loss medicine currently licensed here. Semaglutide, sold as Wegovy, targets the GLP-1 receptor alone. Both are once-weekly subcutaneous injections; you can read more about the broader category of GLP-1 weight-loss injections and what separates them. The mechanism is the same in principle (reduced appetite, slower stomach emptying, steadier blood sugar) but the magnitude of effect differs between medicines and between individuals.

One misconception worth letting go gently: many people expect these injections to speed up metabolism. They don't, primarily. The benefit comes from eating substantially less without the hunger that would normally accompany a calorie deficit. That shift in appetite is what drives the weight loss in trials.

Step 2: what the long-term trial data actually shows

The honest answer about long-term outcomes comes from trials designed to run well past the typical 12-week mark. SURMOUNT-1, which followed more than 2,500 adults over 72 weeks, found average body-weight reductions of around 20–21% at the highest tirzepatide dose, with many participants losing considerably more. The STEP 1 trial, which studied semaglutide 2.4mg over 68 weeks, found an average reduction of around 15%. Both studies are published in the New England Journal of Medicine and represent the strongest available evidence on sustained outcomes.

The catch is visible in the same trial data. When participants stopped treatment at the end of the study period, a substantial portion of the lost weight returned within 12 months. This is not a failure of the person; it reflects a biological truth that obesity medicine increasingly recognises, the hormonal and neural signals that promote weight regain are powerful, and these medicines suppress rather than cure them. NICE's appraisal of tirzepatide acknowledges this when it discusses ongoing treatment review at six months. You can read NICE's recommendations directly in technology appraisal TA1026.

For people asking whether these injections can help with weight loss maintained over the long term, the honest framing is: yes, while on treatment, meaningfully and consistently; the evidence for sustained loss after stopping is much thinner.

Step 3: what clinical assessment and ongoing review look like in practice

Because the evidence points toward treatment being ongoing rather than a finite course, the clinical relationship matters. A prescriber will not simply approve a starting dose and step back. At nume, a named GPhC-registered Independent Prescriber reads your consultation (every first order and every repeat) not software. That clinical re-review happens before each supply; dose increases require evidence; if you are transferring from another provider, your current treatment history is checked.

This kind of oversight shapes how long-term treatment goes well. Side effects are most common in the early weeks, particularly nausea, sometimes vomiting or loose stools; they tend to ease as the body adjusts. Starting at the lower introductory dose (2.5mg for tirzepatide, 0.25mg for semaglutide) gives your system time to settle before the prescriber considers titrating upward. Practically speaking, the injections go into the abdomen, thigh or upper arm, rotating sites each week, details such as storage temperature and the exact injection window are set out in the Patient Information Leaflet for your specific medicine.

If you have conditions beyond weight management (PCOS is a common one) the same injections may offer additional benefits, and our page on whether weight-loss injections can help with PCOS covers what the evidence says there. The range of injections licensed for weight loss in the UK is also worth understanding if you're comparing options before a consultation.

Step 4: understanding access, NHS, private routes and cost

Access to GLP-1 injections on the NHS is phased and criteria-driven. NICE recommends tirzepatide for adults with a BMI of 35 or above and at least one weight-related condition; eligibility thresholds are lower for some ethnic backgrounds under UK guidance. The NHS rollout is expanding gradually, but qualifying criteria are strict and waiting times vary. Many people choose a private route instead (or alongside an NHS referral) to avoid an open-ended wait.

Private treatment through a regulated online pharmacy requires a prescription following proper clinical assessment. What that assessment costs, and what a month's treatment typically costs in the private market, is worth understanding clearly; our weight-loss treatment overview explains what to expect and what should be included in any legitimate price. As a starting point for exploring the process, a fuller picture of how injections to help with weight loss work in the UK is worth reading before deciding whether to proceed.

Whichever route you're considering, the right starting point is a conversation with a prescriber who can assess your situation properly. If you'd like that conversation now, our team is available seven days a week. Speak to our prescribers through a free consultation and get a clinical answer the same day.